Exploring GLP-1 Receptor Agonists: Instagram LIVE Q&A, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 22 July 2024, 18:00 (CEST) to 22 July 2024, 18:30 (CEST)

EMEA-002886-PIP01-20-M03

EMEA-002631-PIP01-19-M02

Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: P/0252/2023

EMEA-002572-PIP02-19-M03

EMEA-002472-PIP03-22-M01

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, Tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0285/2023

Opinion/decision on a Paediatric investigation plan (PIP): Ayvakyt, Avapritinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0281/2023

Opinion/decision on a Paediatric investigation plan (PIP): Prevenar 20 (previously Apexxnar), Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0246/2023

Opinion/decision on a Paediatric investigation plan (PIP): Camzyos, Mavacamten, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiovascular diseases, PIP number: P/0278/2023